There is still some controversy regarding the optimal infused CD34 + dose in allogeneic PBSC transplantation (PBSCT). Several studies have reported that a higher dose of CD34 + cells was associated with a decreased risk of non-relapse mortality (NRM).
1,2
Other authors found that a higher dose of CD34 + cells was associated with a lower relapse rate.
3, 4 In contrast, several studies have reported that a higher dose of infused CD34 + cells was associated with an increased risk of acute or chronic GVHD, which was associated with an inferior overall outcome. 5, 6 Thus, the present study analyzed the impact of the infused CD34 + cell dose on the outcome in related PBSCT.
We retrospectively studied a cohort of 106 adult patients with hematological malignant diseases who received the first related PBSCT at our institute between January 2006 and December 2011. We excluded patients who received haploidentical SCT. The study was approved by the institutional review board of the National Cancer Center, Tokyo, Japan. The probabilities of OS and PFS were calculated with the Kaplan-Meier method. Cumulative incidences of engraftment, NRM, relapse and GVHD were estimated by Gray's method. 7 Variables included in the multivariate analysis were infused cell dose, patient age (linear), donor age (linear), disease stage (early, intermediate or late), conditioning regimen (myeloablative (MAC) or reduced-intensity (RIC)), HLA matching in the GVH direction (matched or 1 locus mismatch), sex mismatch (female to male or other), GVHD prophylaxis (CYA or tacrolimus based), use of MTX, use of antithymocyte globulin (ATG), and year of transplant (2006-2008 or 2009-2011) . All statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University). 8 The median dose of infused CD34 + cells was 3.9 × 10 6 /kg (range, 1.5-12.8). The cut-off points were set at 4.0 × 10 6 /kg for CD34 + cells according to the median infused cell dose. No significant differences were noted between CD34 + cells o4.0 × 10 6 /kg (low-CD34 group) and ⩾ 4.0 × 10 6 /kg (high-CD34 group) with respect to patient characteristics (Table 1 ). The median number of days of neutrophil and platelet engraftment were 12.5 (range, 6-23) and 18 (range, 3-50), respectively. There was no significant difference in the incidences of engraftment of neutrophils (P = 0.61) and platelet (P = 0.56) between the low-CD34 and the high-CD34 groups. The absolute lymphocyte count on day 28 in the high-CD34 group was significantly higher than that in the low-CD34 group (median, 0.87 vs 0.61 × 10 9 /L, P o 0.001). No statistically significant difference in the incidence of grade II-IV (P = 0.97, Figure 1a ), grade III-IV (P = 0.87, Figure 1b ) acute or chronic GVHD (P = 0.84, Figure 1c ) was observed between the low-CD34 and the high-CD34 groups. A higher incidence of grade III-IV acute GVHD was observed in recent years (P = 0.013). The median follow-up time among survivors was 1206 days (range, 253-2224). The cumulative incidences of relapse at 3 years were 62% and 27% in the low-CD34 and high-CD34 groups, respectively (P o 0.001, Figure 1d ). A significantly lower incidence of relapse was observed among patients who received an MAC regimen (P o0.001), whereas no significant difference was observed among patients who received an RIC regimen (P = 0.12). The cumulative incidences of NRM at 3 years were 12% in both groups (P = 0.79, Figure 1e ). The probabilities of OS at 3 years were 36% and 63% in the low- Abbreviations: ATG = antithymocyte globulin; ATL = adult T-cell leukemia/ lymphoma; HL = Hodgkin lymphoma; NHL = non-Hodgkin lymphoma; MDS = myelodysplastic syndrome; TAC = tacrolimus.
a Early disease stage included acute leukemia transplanted in first CR, MDS transplanted either untreated or in first CR, CML in first chronic phase and lymphoma transplanted untreated or in first CR. Intermediate disease stage included acute leukemia in second CR, CML in all stages other than chronic phase or blast crisis, MDS in second CR or in PR and lymphoma in second CR, in PR or stable disease. Late-stage disease included acute leukemia in all other disease stages, CML in blast crisis, MDS in all other disease stages and lymphoma in all other disease stages.
CD34 and high-CD34 groups, respectively (P = 0.028, Figure 1f ). The probabilities of PFS at 3 years were 27% and 60% in the low-CD34 and high-CD34 groups, respectively (P o 0.001, Figure 1g The present results showed that an infused CD34 + cell dose ⩾ 4.0 × 10 6 /kg was associated with a reduced risk of relapse without increasing the risk of GVHD and NRM, which led to a better OS in related PBSCT. In contrast to previous reports, 1,2,9 the CD34 + cell dose had no impact on neutrophil or platelet engraftment in our cohort, whereas a higher infused CD34 + cell dose was associated with a better lymphocyte recovery. We did not find the significant association between infused cell dose of CD34 + and the incidence of acute or chronic GVHD, when we used cut-off values of 4.0 × 10 6 /kg. The mechanism by which a higher infused CD34 + cell dose was likely to reduce the risk of relapse without increasing the risk of GVHD is unclear. One hypothesis is that more rapid lymphocyte recovery after related PBSCT in the high-CD34 group was associated with a reduced risk of relapse, as noted in several previous studies. 10 Decrease of relapse rate in recent years may be explained by the difference in the incidence of acute GVHD, possibly due to the decreased use of ATG in recent years. The limitation of this study should be clarified. Our cohort was possibly underpowered to detect a difference in the incidence of GVHD between the two groups owing to a small sample size. Moreover, this was a retrospective cohort study. Albeit not significant, heterogeneous patient characteristics could partly affect the relapse rate. Our results may not be applicable to unrelated PBSCT.
In conclusion, a higher number of infused CD34 + cells had a positive impact on the clinical outcome after related PBSCT. A prospective study with a larger cohort is needed to reach a definitive conclusion. 
